Back to Search
Start Over
TMEM16A-inhibitor loaded pH-responsive nanoparticles: A novel dual-targeting antitumor therapy for lung adenocarcinoma
- Source :
- Biochemical Pharmacology. 178:114062
- Publication Year :
- 2020
- Publisher :
- Elsevier BV, 2020.
-
Abstract
- To overcome the adverse effects of conventional chemotherapy for cancers, various nanoparticles based drug delivery systems have been developed. However, nanoparticles delivering drugs directly to kill tumor cells still faced with challenges, because tumors possessed adopt complex mechanism to resist damages, which compromised the therapeutic efficacy. TMEM16A/CaCCs (Calcium activates chloride channels) has been identified to be overexpressed in lung adenocarcinoma which can serve as a novel tumor specific drug target in our previous work. Here, we developed a novel dual-targeted antitumor strategy via designing a novel nano-assembled, pH-sensitive drug-delivery system loading with specific inhibitors of TMEM16A against lung adenocarcinoma. For validation, we assayed the novel dual-targeting therapy on xenograft mouse model which exhibited significant antitumor activity and not affect mouse body weight. The dual targeting therapy accomplished in this study will shed light on the development of advanced antitumor strategy.
- Subjects :
- 0301 basic medicine
Lung Neoplasms
Dual targeting
Cell Survival
Mice, Nude
Adenocarcinoma of Lung
Biochemistry
Mice
03 medical and health sciences
Drug Delivery Systems
0302 clinical medicine
Cell Line, Tumor
Animals
Humans
Medicine
Adverse effect
Anoctamin-1
Pharmacology
Lung
Dose-Response Relationship, Drug
business.industry
Hydrogen-Ion Concentration
medicine.disease
Antitumor therapy
Neoplasm Proteins
HEK293 Cells
030104 developmental biology
medicine.anatomical_structure
030220 oncology & carcinogenesis
Drug delivery
Chloride channel
Cancer research
Nanoparticles
Adenocarcinoma
Conventional chemotherapy
business
Subjects
Details
- ISSN :
- 00062952
- Volume :
- 178
- Database :
- OpenAIRE
- Journal :
- Biochemical Pharmacology
- Accession number :
- edsair.doi.dedup.....c377ca902c20c1a91fcba017a69abbba